ArticlePloS one2026
The risk assessment of sleep duration on geriatric sarcopenia and its regulatory role in the effect of BMI index on geriatric sarcopenia based on the CHARLS database.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of sleep duration on geriatric sarcopenia remains unclear, and evidence of the combined impact of it and BMI on geriatric sarcopenia is scarce.
aimsTo conduct the risk assessment of sleep duration on geriatric sarcopenia and explore its moderating role in the effect of BMI on geriatric sarcopenia based on the CHARLS database.
methodsData were extracted from the China Health and Retirement Longitudinal Study (CHARLS) 2011, 2013, and 2015 waves respectively. Logistic regression and Cox regression analyses were conducted to assess the risk of sleep duration for geriatric sarcopenia, and the regulatory effect of sleep duration on the association between BMI and sarcopenia. Subgroup analysis was conducted to enhance the stability of the results.
resultsThe four abnormal types of sleep duration were significantly associated with sarcopenia. A significant association between obesity and decreased risk of sarcopenia was observed in sufficient sleep and sleep deprivation groups after the full adjustment of covariates (Adjusted HR = 0.25, 95%CI: 0.10-0.64, P < 0.001; Adjusted HR = 0.13, 95%CI: 0.03-0.53, P = 0.004; Adjusted HR = 0.26, 95%CI: 0.10-0.66, P = 0.005), and relationships of underweight and overweight with sarcopenia were observed in sufficient sleep, sleep deprivation, and mild oversleeping groups. In the group of oversleeping, the associations were not significant.
conclusionAbnormal sleep durations including sleep deprivation and oversleeping are linked to a heightened risk of sarcopenia among older adults. Underweight is associated with the increased sarcopenia risk, and overweight is correlated with the decreased risk of sarcopenia, especially in females with abnormal sleep duration except for severe oversleeping, and obesity is associated with the decreased risk of sarcopenia, especially in adults aged over 65 with sleep deprivation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.